Table 1.

Demographic and treatment data for 19 treated MDD subjects with corresponding changes of HamD₁₇ scores and PGE-1 stimulated cAMP activity between screen and week 6

ID	age	sex	age of onset	total lifetime episodes	current episode months	study treatment	dose	HAMD17 visit 1	HAMD17 visit 3	PGE1 stimulated adenylyl cyclase*	Percent change adenylyl cyclase*
520	53	F	13	5	2	Duloxetine	60	23	5	−0.46	−24.6%
522	56	F	51	2	unk	Venlafaxine XR	150	21	9	−0.24	−7.9%
524	60	F	15	5	84	Fluoxetine	30	23	10	1.90	131.0%
528	50	M	unk	unk	unk	Escitalopram	10	19	1	2.68	185.0%
534	55	F	9	2	62	Escitalopram	10	18	2	1.19	83.5%
535	57	F	11	5	72	Venlafaxine XR	37.5	18	9	0.58	33.5%
536	43	M	37	3	60	Citalopram	20	17	2	0.60	55.6%
537	57	M	15	2	unk	Citalopram	20	20	8	0.69	48.8%
546	48	M	33	2	180	Escitalopram	20	25	6	−0.86	−25.7%
549	52	F	47	2	53	Escitalopram	10	21	2	1.22	51.2%
501	50	F	31	3	144	Fluoxetine	20	19	9	7.57	151.4%
506	49	F	18	5	22	Nortriptyline	75	18	11	−0.90	−36.5%
507	51	F	13	5	12	Citalopram	40	19	12	−1.84	−52.2%
519	46	M	15	4	120	Duloxetine	90	19	16	−0.48	−13.1%
523	45	F	11	5	72	Citalopram	20	17	10	−1.16	−37.2%
529	59	M	48	3	36	Escitalopram	20	19	13	0.50	3.7%
533	35	F	16	4	6	Escitalopram	10	23	16	0.63	41.5%
542	45	F	40	2	60	Escitalopram	10	26	24	1.12	72.8%
545	50	F	30	3	13	Fluoxetine	20	20	11	−0.40	−15.5%
			Mean change from visit 1 to visit 3 (all subjects)					20.3	9.3	0.65	34.0%
			Mean change from visit 1 to visit 3 (responders)					20.4	5.7	1.35	62.0%
			Mean change from visit 1 to visit 3 (non-responders)					20.1	14.1	−0.32	−4.6%

^*Indicates the change of PGE1 stimulated adenylyl cyclase activity (normalized over basal activity) expressed as nM cAMP/well between the screen (visit 1) and visit 3 (6 weeks of treatment) for each treated subject

NOTE: Subject 520 was taking lorazepam prn and subject 529 was taking zolpidem at the screen visit